GE Healthcare Articles
US FDA briefs: fast-track for Zeltia’s Zentylor; OK for Baxter’s Protopam; warning on gadolinium-based contrast agents
13 September 2010
Ipsen partners with Invida for specialty care drugs in Southeast Asia; Nycomed and GE set up JV for Russia/CIS
27 April 2010
Vernalis to re-acquire EU frovatriptan royalties; Isogenica gains rights to commercialize drugs with MRSA potential
15 February 2010
Molecular Insight appoints Daniel Peters CEO
14 May 2009
Cytori/GH Healthcare partner on StemSource
13 May 2009
Poniard exercises $10M drawn-down option
13 October 2008
Genetix appoints Stephen Game as head of R&D
6 October 2008
Novavax licenses VLP bird flu vacc to GE Healthcare
1 September 2008
GE reports good results in Ph I PET agent trial
11 August 2008
GE Healthcare in deal with Merck & Co
12 May 2008
Two senior appointments at Illumina
24 March 2008
GE Healthcare provides $95M facility to EKR
17 March 2008
Astex gets L7.5M loan for development work
17 December 2007
New technique to see if cancer treatment works
10 December 2007
GE and Lilly to collaborate on cancer drug analysis
22 October 2007
Early Health benefits and obstacles revealed by EU study
8 October 2007
OGT and Applied Microarrays sign licensing deal
9 July 2007
Biacore debuts new system for protein interaction analysis
26 February 2007
Japan stock market week to Jan 15, 2007
22 January 2007
CHMP Update on current activities
10 July 2006
GE Healthcare bids for Biacore
3 July 2006
Biacore launches its own operation in China
22 May 2006
Roche/GE sign deal for personalized AD drugs
18 July 2005
Daiichi FY2005 net income soars 39%
16 May 2005
Repligen and GE Healthcare expand Protein A supply deal
14 February 2005
NascaCell in Japanese aptamer distribution deal with GE
1 November 2004
Showing 1-32 of 32 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
